晚期NSCLC靶向治疗-ASCO新进展 TOPIC3.pptxVIP

晚期NSCLC靶向治疗-ASCO新进展;;;4;5;NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutationsNEJ026：贝伐珠单抗联合厄洛替尼治疗EGFR突变阳性NSCLC患者的最终OS分析;研究设计：NEJ026(III期研究);最终OS及亚组分析;First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NC一线TKI联合或未联合前期积极局部放疗治疗EGFR突变的寡转移的NSCLC患者：一项随机开放三期研究的中期分析(SINDAS) (NC;研究方法;KM生存曲线PFS(A)和OS(B);多变量分析